Hyperoside protects cardiomyocytes against hypoxia‑induced injury via upregulation of microRNA‑138

金丝桃苷通过上调 microRNA-138 保护心肌细胞免受缺氧引起的损伤

阅读:10
作者:Siyi He, Xiaoqiang Yin, Fan Wu, Shaojie Zeng, Feng Gao, Mei Xin, Jian Wang, Jie Chen, Le Zhang, Jinbao Zhang

Abstract

Following hypoxia, cardiomyocytes are susceptible to damage, against which microRNA (miR)‑138 may act protectively. Hyperoside (Hyp) is a Chinese herbal medicine with multiple biological functions that serve an important role in cardiovascular disease. The aim of the present study was to investigate the role of Hyp in hypoxic cardiomyocytes and its effect on miR‑138. A hypoxia model was established in both H9C2 cells and C57BL/6 mice, which were stimulated by Hyp. The expression levels of miR‑138 were increased in the hypoxic myocardium in the presence of Hyp at concentrations of >50 µmol/l in vivo and >50 mg/kg in vitro. Using Cell Counting Kit‑8 and 5‑ethynyl‑2'‑deoxyuridine assays, it was observed that Hyp improved hypoxia‑induced impairment of cell proliferation. Cell apoptosis was evaluated by flow cytometry and a TUNEL assay. The number of apoptotic cells in the Hyp group was lower than that in the control group. As markers of myocardial injury, the levels of lactate dehydrogenase, creatine kinase‑myocardial band isoenzyme and malondialdehyde were decreased in the Hyp group compared with the control group, whereas the levels of superoxide dismutase were increased. A marked decrease in the levels of cleaved caspase‑3 and cleaved poly(ADP) ribose polymerase and a marked increase in expression levels of Bcl‑2 were observed in the presence of Hyp. However, miR‑138 inhibition by antagomir attenuated the protective effects of Hyp. Furthermore, Hyp treatment was associated with marked downregulation of mixed lineage kinase 3 and lipocalin‑2, but not pyruvate dehydrogenase kinase 1, in hypoxic H9C2 cells. These findings demonstrated that Hyp may be beneficial for myocardial cell survival and may alleviate hypoxic injury via upregulation of miR‑138, thereby representing a promising potential strategy for clinical cardioprotection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。